Author Index to Volume 50

Aardal-Eriksson E, Eriksson TE, Thorell L-H. Salivary cortisol, posttraumatic stress symptoms, and general health in the acute phase and during 9-month follow-up, 986
Abend S. See King JA
Abercrombie HC. See Rusch BD
Adams BW, Moghaddam B. Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex, 750
Ahearn EP, Jamison KR, Steffens DC, Cassidy F, Provenzale JM, Lehman A, Weisler RH, Carroll BJ, Krishnan KRR. MRI correlates of suicide attempt history in unipolar depression, 266
Albers M. See Owega A
Alborzian S. See Saxena S
Alpert J. See Lavori PW
Alpert NM. See Rauch SL
Altemus M. See Coplan JD
Altman E, Hedeker D, Peterson JL, Davis JM. A comparative evaluation of three self-rating scales for acute mania, 468
Altshuler LL. See Hendrick V
Alvarez JC. See Quintin P
Amsterdam JD. See Szuba MP
Anvar B. See Narr KL
Araujo AB. See Seidman SN
Ardekani B. See Pine DS
Arman A. See Morshed SA
Arnulf I. See Quintin P
Aschauer HN. See Willeit M
Asenbaum S. See Willeit M
Au SC. See Saxena S
Austen ML, Wilson GV. Increased vagal tone during winter in subsyndromal seasonal affective disorder, 28
Avery DH, Eder DN, Bolte MA, Hellekson CJ, Dunner DL, Vitiello MV, Prinz PN. Dawn simulation and bright light in the treatment of SAD: a controlled study, 205
Avila MT, Conley RR, Carpenter WT Jr. A comparison of symptom provocation procedures in psychiatry and other areas of medicine: implications for their ethical use in research, 479

Baader M. See Thome J
Baer L. See Rauch SL
Barbault S. See Quintin P
Barch DM. See Sheline YI
Bartko JJ. See van de Laar N
Bartoli A. See Nacmias B
Basile VS. See Levitan RD
Bastain TM. See Gould TD
Bauer LO, Hesselbrock VM. CSD/BEM localization of P300 sources in adolescents "at risk": evidence of frontal cortex dysfunction in conduct disorder, 600
Baxter LR Jr. See Saxena S
Becker G. See Berg D
Beckmann H. See Berg D
Bédard PJ. See Tekumalla PK
Beersma DGM. See Koorengevel KM
Belger A. See Lieberman JA
Bench CJ. See Montgomery AJ
Benes FM, Vincent SL, Todtenkopf M. The density of pyramidal and nonpyramidal neurons in anterior cingulate cortex of schizophrenic and bipolar subjects, 395
Benkelfat C. See Quintin P
Benson B. See Osuch EA
Berg D, Jabs B, Merschdorf U, Beckmann H, Becker G. Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy, 463
Berman KF. See Weinberger DR
Bertolino A. See Weinberger DR
Bertolot J. See Croft RJ
Bhagwager Z. See Montgomery AJ
Biederman J. See Faraone SV
Bienvenu OJ. See Grados MA
Bigelow L. See Egan MF
Bilder RM. See Pine DS
Binder EB, Kinkead B, Owens MJ, Nemeroff CB. The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs, 856
Birdi S. See Tekumalla PK
Blankenstein MA. See Thijssen JPP
Blanton R. See Narr KL
Blier P. See Haddjeri N
Blier P. See Szabo ST
Blom JMC. See Tascedda F
Bohning DE. See Nahas Z
Bollen ELEM. See van den Heuvel DMJ
Bolte MA. See Avery DH
Bondy B. See Preuss UW
Boring AM. See De Bellis MD
Bosker FJ. See Cremers TIFH
Boteva K. See Lieberman JA
Botteron KN. See Todd RD
Braff DL. See Perry W
Brambilla P. See Sassi RB
Bravi D. See Tascedda F
Bremner JD. See Rasmusson AM
Breslau N, Kessler RC. The stressor criterion in DSM-IV posttraumatic stress disorder: an empirical study, 699
Brewer WJ. See Velakoulis D
Briegel J. See Schelling G
Brink J. See Kiehl KA
Brody AL. See Saxena S
Brook J. See Pine DS
Brown W. See Carrion VG
Brücke T. See Willeit M
Bruder GE, Kayser J, Tenke CE, Friedman M, Malaspina D, Gorman JM. Event-related potentials in schizophrenia during tonal and phonetic oddball tasks: relations to diagnostic subtype, symptom features and verbal memory, 447
Brunello N. See Tascedda F
Buchsbaum MS. See Hazlett EA
Buckley PF. Broad therapeutic uses of atypical antipsychotic medications, 912
Burgess N. See Pine DS
Burt T, Lane RM. Forced titration as a confound in an SSRI comparator

Abbreviations:
ed: editorial
corr: correspondence

© 2001 Society of Biological Psychiatry

0006-3223/01/$20.00
PII S0006-3223(01)01340-3

study of sertraline versus citalopram in the treatment of major depressive disorder, 66–corr
Bush G. See Shin LM
Butters MA. See Fabian TJ
Byne W. See Hazlett EA

Callicott JH. See Weinberger DR
Calon F. See Tekumalla PK
Camfferman G. See van der Geest JN
Campbell AM. See Park CR
Canick JD. See Neylan TC
Carpenter WT Jr. See Avila MT
Carra S. See Tascedda F
Carrion VG, Weems CF, Eliez S, Patwardhan A, Brown W, Ray RD, Reiss AL. Attenuation of frontal asymmetry in pediatric posttraumatic stress disorder, 943
Carroll BJ. See Ahearn EP
Cassem EH. See Rauch SL
Cassidy F. See Ahearn EP
Castellanos FX. See Gould TD
Chakos M. See Lieberman JA
Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia, 71
Charney DS. See Rasmusson AM
Charney DS, Innis RB, Nestler EJ, Manji HK. Update: what's new in *Biological Psychiatry,* 1–ed
Chen B, Dowlatshahi D, MacQueen GM, Wang J-F, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication, 260
Chong S-A. See Tan E-C
Cohen PJ. See Pine DS
Colzi A. See Tascedda F
Conley RR. See Avila MT
Conley RR, Kelly DL. Management of treatment resistance in schizophrenia, 898
Consogno E, Tiraboschi E, Iuliano E, Gennarelli M, Racagni G, Popoli M. Long-term treatment with S-adenosylmethionine induces changes in presynaptic CaM kinase II and synapsin I, 337
Cooke RG. See Yoon I-S
Cooper TB. See Parsey RV
Coplan JD, Smith ELP, Altemus M, Scharf BA, Owens MJ, Nemeroff CB, Gorman JM, Rosenblum LA. Variable foraging demand rearing: sustained elevations in cisternal cerebrospinal fluid corticotropin-releasing factor concentrations in adult primates, 200
Copolov D. See Velakoulis D
Coppola R. See Winterer G
Cosgrove GR. See Rauch SL
Cremers TIFH, Wiersma LJ, Bosker FJ, den Boer JA, Westerink BHC, Wikström HV. Is the beneficial antidepressant effect of coadministration of pindolol really due to somatodendritic autoreceptor antagonism?, 13
Croft RJ, Lee A, Bertolot J, Gruzelier JH. Associations of P50 suppression and desensitization with perceptual and cognitive features of "unreality" in schizotypy, 441
Cusin C. See Zanardi R

Daan S. See Koorengevel KM
Danckaerts M. See van Os J
Davidson RJ. See Rusch BD
Davis JM. See Altman E
Dawe GS, Huff KD, Vandergriff JL, Sharp T, O'Neill MJ, Rasmussen K. Olanzapine activates the rat locus coeruleus: in vivo electrophysiology and c-fos immunoreactivity, 510
De Bellis MD, Hall J, Boring AM, Frustaci K, Moritz G. A pilot longitudinal study of hippocampal volumes in pediatric maltreatment-related posttraumatic stress disorder, 305
DeMartinis N. See Furlan PM
Demopulos CM. See Yildiz A
den Boer JA. See Cremers TIFH
den Boer JA. See Koorengevel KM
den Heeten GJ. See Reneman L
Derom C. See van Os J
Desmond P. See Velakoulis D
Dew MA. See Fabian TJ
Diamond DM. See Park CR
Dieter R. See Gann H
Dietrich TM. See Herpertz SC
Di Paolo T. See Tekumalla PK
Dobie DJ. See Kanter ED
Dong F. See Tan E-C
Donnelly JM. See Sheline YI
Dotoli D. See Zanardi R
Dougherty DD. See Rauch SL
Dowlatshahi D. See Chen B
Doyle AE. See Faraone SV
D'Souza DC. See Krystal JH
Du AT. See Schuff N
Duman RS. See Thome J
Dunner DL. See Avery DH
Dvoskin R, Suomi SJ, Shoaf S. No detectable prolactin in human saliva, 818–corr (reply)

Eastvold A. See Swerdlow NR
Eder DN. See Avery DH
Edris A. See Narr KL
Edwards E. See King JA
Egan MF. See Weinberger DR
Egan MF. See Winterer G
Egan MF, Goldberg TE, Gscheidle T, Weirich M, Rawlings R, Hyde TM, Bigelow L, Weinberger DR. Relative risk for cognitive impairments in siblings of patients with schizophrenia, 98
Ehlers CL, Wall TL, Garcia-Andrade C, Phillips E. EEG asymmetry: relationship to mood and risk for alcoholism in mission Indian youth, 129
Elbert T. See Fehr T
Eliez S. See Carrion VG
Ellis SP. See Placidi GPA
Erberich SG. See Herpertz SC
Eriksson TE. See Aardal-Eriksson E
Evans DL. See Szuba MP
Eyeler J. See Wirshing DA

Fabian TJ, Dew MA, Pollock BG, Reynolds CF III, Mulsant BH, Butters MA, Zmuda MD, Linares AM, Trottini M, Kroboth PD. Endogenous concentrations of DHEA and DHEA-S decrease with remission of depression in older adults, 767
Faraone SV See Kremen WS
Faraone SV See Stone WS
Faraone SV, Biederman J, Mick E, Doyle AE, Wilens T, Spencer T, Frazier E., Mullen K. A family study of psychiatric comorbidity in girls and boys with attention-deficit/hyperactivity disorder, 586
Faustman WO. See Ford JM
Fava M. See Lavori PW
Fehr T, Kissler J, Moratti S, Wienbruch C, Rockstroh B, Elbert T. Source distribution of neuromagnetic slow waves and MEG-delta activity in schizophrenic patients, 108
Feifel D. See Perry W

Feifel D, Priebe K. Vasopressin-deficient rats exhibit sensorimotor gating deficits that are reversed by subchronic haloperidol, 425
Feige B. See Gann H
Fein D. See Green L
Feinstein C. See Green L
Fischer P. See Graf A
Fischman AJ. See Rauch SL
Fleischman MB. See Hazlett EA
Fong GW. See Knutson B
Ford JM, Mathalon DH, Kalba S, Whitfield S, Faustman WO, Roth WT. Cortical responsiveness during talking and listening in schizophrenia: an event-related brain potential study, 540
Forleo P. See Nacmias B
Forster BB. See Kiehl KA
Fourneret P. See Perchet C
Franchini L. See Zanardi R
Frank E. See Sassi RB
Frazier E. See Faraone SV
Freedman R. See Simosky JK
Freeman EW. See Morrison MG
Friedman E. See Wang H-Y
Friedman M. See Bruder GE
Frustaci K. See De Bellis MD
Fuchs K. See Willeit M
Fujii T. See Morshed SA
Fukuchi A. See Hendrick V
Furlan PM, DeMartinis N, Schweizer E, Rickels K, Lucki I. Abnormal salivary cortisol levels in social phobic patients in response to acute psychological but not physical stress, 254
Fyer A. See Pine DS

Gann H, Feige B, Hohagen F, van Calker D, Geiss D, Dieter R. Sleep and the cholinergic rapid eye movement sleep induction test in patients with primary alcohol dependence, 383
Garcia-Andrade C. See Ehlers CL
Garcia-Larrea L. See Perchet C
Geiss D. See Gann H
Gelernter J. See New AS
Gennarelli M. See Consogno E
Gennarelli M. See Tascedda F
George MS. See Nahas Z
Geraci M. See Osuch EA
Gerlach J. See Peacock L
Gettes DR. See Szuba MP
Gewirtz JC. See Thome J
Geyer MA. See Swerdlow NR
Gilmore J. See Lieberman JA
Gilmore J. See Marx CE
Goldberg TE. See Egan MF
Goldberg TE. See Weinberger DR
Goodman M. See New AS
Goodyer IM, Park RJ, Herbert J. Psychosocial and endocrine features of chronic first-episode major depression in 8–16 year olds, 351
Gordijn MCM See Koorengevel KM
Gorman JM. See Bruder GE
Gorman JM. See Coplan JD
Gould TD, Bastain TM, Israel ME, Hommer DW, Castellanos FX. Altered performance on an ocular fixation task in attention-deficit/hyperactivity disorder, 633
Grados MA, Riddle MA, Samuels JF, Liang K-Y, Hoehn-Saric R, Bienvenu OJ, Walkup JT, Song D, Nestadt G. The familial phenotype of obsessive-compulsive disorder in relation to tic disorders: the Hopkins OCD family study, 559
Graf A, Wallner C, Schubert V, Willeit M, Wlk W, Fischer P, Kasper S, Neumeister A. The effects of light therapy on Mini-Mental State Examination scores in demented patients, 725
Grant MM. See Weiss JM
Grant MM, Thase ME, Sweeney JA. Cognitive disturbance in outpatient depressed younger adults: evidence of modest impairment, 35
Grasby P. See Montgomery AJ
Green AI. See Stone WS
Green L, Fein D, Modahl C, Feinstein C, Waterhouse L, Morris M. Oxytocin and autistic disorder: alterations in peptide forms, 609
Greenberg BD. See Wassermann EM
Grisso JA. See Morrison MG
Grun J. See Pine DS
Gruzelier JH. See Croft RJ
Gscheidle T. See Egan MF
Guarnieri BM. See Nacmias B
Gunn, RN. See Montgomery AJ

Haddjeri N, Blier P. Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission, 191
Hall J. See De Bellis MD
Hall SE. See Neylan TC
Hammers A. See Montgomery AJ
Hare RD. See Kiehl KA
Harenski K. See Sassi RB
Hazlett EA, Buchsbaum MS, Tang CY, Fleischman MB, Wei T-C, Byne W, Haznedar MM. Thalamic activation during an attention-to-prepulse startle modification paradigm: a functional MRI study, 281
Haznedar MM. See Hazlett EA
Heckers S. See Konradi C
Hedeker D. See Altman E
Hellekson CJ. See Avery DH
Hendrick V, Stowe ZN, Altshuler LL, Mintz J, Hwang S, Hostetter A, Suri R, Leight K, Fukuchi A. Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk, 775
Henn FA. See Thome J
Henter I. See van de Laar N
Herbert J. See Goodyer IM
Herpertz SC, Dietrich TM, Wenning B, Krings T, Erberich SG, Willmes K, Thron A, Sass H. Evidence of abnormal amygdala functioning in borderline personality disorder: A functional MRI study, 292
Herscovitch P. See Osuch EA
Herwig U, Padberg F, Unger J, Spitzer M, Schönfeldt-Lecuona C. Transcranial magnetic stimulation in therapy studies: examination of the reliability of "standard" coil positioning by neuronavigation, 58
Hesselbrock VM. See Bauer LO
Higuchi S. See Nishiguchi N
Ho MK. See Saxena S
Ho ML. See Saxena S
Hoehn-Saric R. See Grados MA
Hohagen F. See Gann H
Hommer B. See Knutson B
Hommer DW. See Gould TD
Hornik K. See Willeit M
Hornykiewicz O. See Tekumalla PK
Hostetter A. See Hendrick V
Hu M. See Thome J
Hu S. See Rasmusson AM
Huang S-C. See Saxena S
Huang Y-Y. See Placidi GPA
Huff KD. See Dawe GS
Hwang S. See Hendrick V
Hyde TM. See Egan MF

Innis RB. See Charney DS
Israel ME. See Gould TD
Iuliano E. See Consogno E

Jabs B. See Berg D

Jamison KR. See Ahearn EP
Jarskog F. See Lieberman JA
Jarskog F. See Marx CE
Jenike MA. See Rauch SL
Jentsch JD. See Taylor JR
Jouvent R. See Quintin P

Kalba S. See Ford JM
Kanter ED, Wilkinson CW, Radant AD, Petrie EC, Dobie DJ, McFall ME, Peskind ER, Raskind MA. Glucocorticoid feedback sensitivity and adrenocortical responsiveness in posttraumatic stress disorder, 238
Kapfhammer H-P. See Schelling G
Kaplan AS. See Levitan RD
Kapur S, Remington G. Dopamine D_2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient, 873
Kapur S, Seeman P. Comment on "Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D_2 receptor," 555–corr (reply)
Karban B. See Swerdlow NR
Kasper S. See Graf A
Kasper S. See Willeit M
Kayser J. See Bruder GE
Kegeles LS. See Parsey RV
Kelly DL. See Conley RR
Kemner C. See van der Geest JN
Ken WR. See Simosky JK
Kennedy JL. See Levitan RD
Kennedy JL. See Yoon I-S
Kennedy SH. See Levitan RD
Keshavan MS. See Sassi RB
Kessler RC. See Breslau N
Khaledy M. See Narr KL
Kiehl KA, Smith AM, Hare RD, Mendrek A, Forster BB, Brink J, Liddle PF. Limbic abnormalities in affective processing by criminal psychopaths as revealed by functional magnetic resonance imaging, 677
Kilts CD. The changing roles and targets for animal models of schizophrenia, 845
King JA, Abend S, Edwards E. Genetic predisposition and the development of posttraumatic stress disorder in an animal model, 231
King RA. See Morshed SA
Kinkead B. See Binder EB
Kiss MHB. See Morshed SA
Kissler J. See Fehr T
Klingelhöfer J. See Owega A
Knight DL. See Owens MJ
Knutson B, Momenan R, Rawlings R, Fong GW, Hommer D. Negative association of neuroticism with brain volume ratio in healthy humans, 685
Koda V. See Pine DS
Koenigsberg H. See New AS
Koller G. See Preuss UW
Konradi C, Heckers S. Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia, 729
Koorengevel KM, Gordijn MCM, Beersma DGM, Meesters Y, den Boer JA, van den Hoofdakker RH, Daan S. Extraocular light therapy in winter depression: a double-blind placebo-controlled study, 691
Kremen WS, Seidman LJ, Faraone SV, Tsuang MT. Intelligence quotient and neuropsychological profiles in patients with schizophrenia and in normal volunteers, 453
Krings T. See Herpertz SC
Krishnan KRR. See Ahearn EP
Krishnan KRR. See Steffens DC
Krishnan KRR. See Taylor WD
Kroboth PD. See Fabian TJ
Krupp R. See Narr KL
Krystal JH. See Chambers RA
Krystal JH, D'Souza DC. Comment on "Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D_2 receptor," 555–corr
Kupfer DJ. See Lavori PW
Kupfer DJ. See Sassi RB

Lane RM. See Burt T
Laruelle M. See Parsey RV
Lasko NB. See Shin LM
Lattuada E. See Zanardi R
Lauder JM. See Marx CE
Launay JM. See Quintin P
Lavori PW, Rush AJ, Wisniewski SR, Alpert J, Fava M, Kupfer DJ, Nierenberg A, Quitkin FM, Sackeim HA, Thase ME, Trivedi M. Strengthening clinical effectiveness trials: equipoise-stratified randomization, 792
Leboyer M. See Quintin P
Leckman JF. See Morshed SA
Lee A. See Croft RJ
Lee MA, Meltzer HY. 5-HT_{1A} receptor dysfunction in female patients with schizophrenia, 758
Lehman A. See Ahearn EP
Leight K. See Hendrick V
Lenoci MA. See Schuff N
Levitan RD, Kaplan AS, Masellis M, Basile VS, Walker ML, Lipson N., Siegel GI, Woodside DB, Macciardi F, Kennedy SH, Kennedy JL. Polymorphism of the serotonin 5-HT1B receptor gene (HTR1B) associated with minimum lifetime body mass index in women with bulimia nervosa, 640
Li PP. See Yoon I-S
Li W. See Pine DS
Li X. See Nahas Z
Liang K-Y. See Grados MA
Liddle PF. See Kiehl KA
Lieberman JA. See Marx CE
Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches, 884
Linares AM. See Fabian TJ
Lipschitz DS. See Rasmusson AM
Lipska BK. See Weinberger DR
Lipson N. See Levitan RD
Lomarev M. See Nahas Z
Lombroso PJ. See Morshed SA
Lorberbaum JP. See Nahas Z
Lucki I. See Furlan PM

Macciardi F. See Levitan RD
Macciardi F. See Yoon I-S
MacFall JR. See Taylor WD
Macklin ML. See Shin LM
MacQueen GM. See Chen B
Maguire EA. See Pine DS
Mahendran R. See Tan E-C
Maidment KM. See Saxena S
Majoie CBLM. See Reneman L
Malaspina D. See Bruder GE
Mallinger AG. See Sassi RB
Malone KM. See Placidi GPA
Manji HK. See Charney DS
Manji HK. See Rapaport MH
Mann JJ. See Parsey RV
Mann JJ. See Placidi GPA
Marcon G. See Nacmias B
Marmar CR. See Schuff N
Marx CE, Jarskog F, Lauder JM, Lieberman JA, Gilmore J. Cytokine effects on cortical neuron MAP-2

immunoreactivity: implications for schizophrenia, 743
Masellis M. See Levitan RD
Mathalon DH. See Ford JM
Matsushita S. See Nishiguchi N
Mattay VS. See Weinberger DR
Matute LMP. See Thijssen JPP
Mauguière F. See Perchet C
Mayberg HS. See Rauch SL
McCann UD. See Osuch EA
McConnell K. See Nahas Z
McFall ME. See Kanter ED
McInerney SC. See Shin LM
McKinlay JB. See Seidman SN
McQuoid DR. See Steffens DC
Medoff D. See Schwarcz R
Meesters Y. See Koorengevel KM
Meltzer HY. See Lee MA
Mendrek A. See Kiehl KA
Mercadante MT. See Morshed SA
Merschdorf U. See Berg D
Mick E. See Faraone SV
Middelkoop HAM. See van den Heuvel DMJ
Miguel EC. See Morshed SA
Miller FG. See Rosenstein DL
Minassian A. See Perry W
Mintum MA. See Sheline YI
Mintz J. See Hendrick V
Mitropoulou V. See New AS
Modahl C. See Green L
Moghaddam B. See Adams BW
Momenan R. See Knutson B
Montgomery AJ, Bench CJ, Young AH, Hammers A., Gunn RN, Bhagwager Z, Grasby P. PET measurement of the influence of corticosteroids on serotonin-1A receptor number, 668
Moore CM. See Yildiz A
Moratti S. See Fehr T
Moritz G. See De Bellis MD
Morris M. See Green L
Morrison MF, Ten Have T, Freeman EW, Sammel MD, Grisso JA. DHEA-S levels and depressive symptoms in a cohort of African American and Caucasian women in the late reproductive years, 705
Morshed SA, Parveen S, Leckman JF, Mercadante MT, Kiss MHB, Miguel EC, Arman A, Yazgan Y, Fujii T, Paul S, Peterson BS, Zhang H, King RA, Scahill L, Lombroso PJ. Antibodies against neural, nuclear, cytoskeletal, and streptococcal epitopes in children and adults with Tourette's syndrome, Sydenham's chorea, and autoimmune disorders, 566
Moussai J. See Narr KL
Mullen K. See Faraone SV
Mulsant BH. See Fabian TJ
Murayama M. See Nishiguchi N
Murphy DL. See Wassermann EM

Nacmias B, Tedde A, Forleo P, Piacentini S, Guarnieri BM, Bartoli A, Ortenzi L, Petruzzi C, Serio A, Marcon G, Sorbi S. Association between 5-HT_{2A} receptor polymorphism and psychotic symptoms in Alzheimer's disease, 472
Nahas Z, Lomarev M, Roberts DR, Shastri A, Lorberbaum JP, Teneback C, McConnell K, Vincent DJ, Li X, George MS, Bohning DE. Unilateral left prefrontal transcranial magnetic stimulation (TMS) produces intensity-dependent bilateral effects as measured by interleaved BOLD fMRI, 712
Narr KL, Thompson PM, Sharma T, Moussai J, Blanton R, Anvar B, Edris A, Krupp R, Rayman J, Khaledy M, Toga AW. Three-dimensional mapping of temporo-limbic regions and the lateral ventricles in schizophrenia: gender effects, 84
Nemeroff CB. See Binder EB
Nemeroff CB. See Coplan JD
Nemeroff CB. See Owens MJ
Nemeroff CB. New perspectives on the neurobiology of schizophrenia and the role of atypical antipsychotics: introduction, 823–ed
Nestadt G. See Grados MA
Nestler EJ. See Charney DS
Nestler EJ. See Tekumalla PK
Neumeister A. See Graf A
Neumeister A. See Willeit M
New AS, Gelernter J, Goodman M, Mitropoulou V, Koenigsberg H, Silverman J, Siever LJ. Suicide, impulsive aggression, and HTR1B genotype, 62
Neylan TC. See Schuff N
Neylan TC, Canick JD, Hall SE, Reus VI, Sapolsky RM, Wolkowitz OM. Cortisol levels predict cognitive impairment induced by electroconvulsive therapy, 331
Nguyen MB. See Wassermann EM
Nicoletti M. See Sassi RB
Nierenberg A. See Lavori PW
Nierenberg A. See Rauch SL
Nishiguchi N, Matsushita S, Suzuki K, Murayama M, Shirakawa O, Higuchi S. Association between 5HT2A receptor gene promoter region polymorphism and eating disorders in Japanese patients, 123

Oakes TR. See Rusch BD
Ollinger JM. See Sheline YI
O'Neill MJ. See Dawe GS
Oquendo MA. See Parsey RV
Oquendo MA. See Placidi GPA
O'Reardon JP. See Szuba MP
Orr SP. See Shin LM
Ortenzi L. See Nacmias B
Osuch EA, Benson B, Geraci M, Podell D, Herscovitch P, McCann UD, Post RM. Regional cerebral blood flow correlated with flashback intensity in patients with posttraumatic stress disorder, 246
Owega A, Sabri O, Klingelhöfer J, Albers M. Cerebral blood flow velocity in untreated panic disorder patients: a transcranial Doppler ultrasonography study, 299
Owens MJ. See Binder EB
Owens MJ. See Coplan JD
Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and *R*-fluoxetine, 345

Padberg F. See Herwig U
Pantelis C. See Velakoulis D
Parikh SV. See Yoon I-S
Park CR, Campbell AM, Diamond DM. Chronic psychosocial stress impairs learning and memory and increases sensitivity to yohimbine in adult rats, 994
Park RJ. See Goodyer IM
Parsey RV, Oquendo MA, Zea-Ponce Y, Rodenhiser J, Kegeles LS, Pratap M, Cooper TB, Van Heertum R, Mann JJ, Laruelle M. Dopamine D_2 receptor availability and amphetamine-induced dopamine release in unipolar depression, 313
Parveen S. See Morshed SA
Patwardhan A. See Carrion VG
Paul S. See Morshed SA
Payne ME. See Taylor WD

Peacock L, Gerlach J. Aberrant behavioral effects of a dopamine D1 receptor antagonist and agonist in monkeys: evidence of uncharted dopamine D1 receptor actions, 501
Perchet C, Revol O, Fourneret P, Mauguière F, Garcia-Larrea L. Attention shifts and anticipatory mechanisms in hyperactive children: an ERP study using the Posner paradign, 44
Perez-Diaz F. See Quintin P
Perkins D. See Lieberman JA
Perry W, Minassian A, Feifel D, Braff DL. Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania, 418
Peskind ER. See Kanter ED
Pesold B. See Thome J
Peterson BS. See Morshed SA
Peterson JL. See Altman E
Petrie EC. See Kanter ED
Petruzzi C. See Nacmias B
Phelps EA. See Pine DS
Phillips E. See Ehlers CL
Piacentini S. See Nacmias B
Pierre JM. See Wirshing DA
Pine DS, Cohen PJ, Brook J. Adolescent fears as predictors of depression, 721
Pine DS, Fyer A, Grun J, Phelps EA, Szeszko PR, Koda V, Li W, Ardekani B, Maguire EA, Burgess N, Bilder RM. Methods for developmental studies of fear conditioning circuitry, 225
Pirebe K. See Feifel D
Pirker W. See Willeit M
Pitman RK. See Shin LM
Placidi GPA, Oquendo MA, Malone KM, Huang Y-Y, Ellis SP, Mann JJ. Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fluid monoamine metabolite levels, 783
Ploum Y. See Swerdlow NR
Podell D. See Osuch EA
Pointereau-Bellenger A. See Quintin P
Pollock BG. See Fabian TJ
Popoli M. See Consogno E
Post RM. See Osuch EA
Praschak-Rieder N. See Willeit M
Pratap M. See Parsey RV
Preuss UW, Koller G, Soyka M, Bondy B. Association between suicide attempts and 5-HTTLPR-S-allele in alcohol-dependent and control subjects: further evidence from a German alcohol-dependent inpatient sample, 636
Price BH. See Rauch SL
Prinz PN. See Avery DH
Provenzale JM. See Ahearn EP
Provenzale JM. See Taylor WD

Quintin P, Benkelfat C, Launay JM, Arnulf I, Pointereau-Bellenger A, Barbault S, Alvarez JC, Varoquaux O, Perez-Diaz F, Jouvent R, Leboyer M. Clinical and neurochemical effect of acute tryptophan depletion in unaffected relatives of patients with bipolar affective disorder, 184
Quitkin FM. See Lavori PW

Racagni G. See Consogno E
Racagni G. See Tascedda F
Radant AD. See Kanter ED
Rädler T. See Winterer G
Rahman Z. See Tekumalla PK
Rai AS. See Szuba MP
Rajput AH. See Tekumalla PK
Rapaport MH, Manji HK. The effects of lithium on ex vivo cytokine production, 217
Raskind MA. See Kanter ED
Rasmussen K. See Dawe GS
Rasmusson AM, Lipschitz DS, Wang S, Hu S, Vojvoda D, Bremner JD, Southwick SM, Charney DS. Increased pituitary and adrenal reactivity in premenopausal women with PTSD, 965
Rassoulpour A. See Schwarcz R
Rauch SL. See Shin LM
Rauch SL, Dougherty DD. Cosgrove GR, Cassem EH, Alpert NM, Price BH, Nierenberg A, Mayberg HS, Baer L, Henike MA, Fischman AJ. Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for obsessive compulsive disorder, 659
Rawlings R. See Egan MF
Rawlings R. See Knutson B
Ray RD. See Carrion VG
Rayman J. See Narr KL
Reiss AL. See Carrion VG
Remington G. See Kapur S
Reneman L. Majoie CBLM, Schmand B, van den Brink W, den Heeten GJ. Prefrontal *N*-acetylaspartate is strongly associated with memory performance in (abstinent) ecstasy users: preliminary report, 550
Renshaw PF. See Yildiz A
Reus VI. See Neylan TC
Revol O. See Perchet C
Reynolds CF III. See Fabian TJ
Riberts DR. See Nahas Z
Rickels K. See Furlan PM
Riddle MA. See Grados MA
Riva MA. See Tascedda F
Roberts RC. See Schwarcz R
Rockstroh B. See Fehr T
Rodenhiser J. See Parsey RV
Roose SP. See Seidman SN
Roozendaal B. See Schelling G
Rosenblum LA. See Coplan JD
Rosenstein DL, Miller FG, Rubinow DR. A curriculum for teaching psychiatric research bioethics, 802
Rosenthal NE. See Schwartz PJ
Rossini D. See Zanardi R
Roth WT. See Ford JM
Rothenhäusler H-B. See Schelling G
Rubinow DR. See Rosenstein DL
Rusch BD, Abercrombie HC, Oakes TR, Schaefer SM, Davidson RJ. Hippocampal morphometry in depressed patients and control subjects: relations to anxiety symptoms, 960
Rush AJ. See Lavori PW

Sabri O. See Owega A
Sachs GS. See Yildiz A
Sackeim HA. See Lavori PW
Sammel MD. See Morrison MG
Samuels JF. See Grados MA
Sapolsky RM. See Neylan TC
Sass H. See Herpertz SC
Sassi RB, Nicoletti M, Brambilla P, Harenski K, Mallinger AG, Frank E, Kupfer DJ, Keshavan MS, Soares JC. Decreased pituitary volume in patients with bipolar disorder, 271
Saxena S, Brody AL, Ho ML, Alborzian S, Ho MK, Maidment KM, Huang S-C, Wu H-M, Au SC, Baxter LR Jr. Cerebral metabolism in major depression and obsessive-compulsive disorder occurring separately and concurrently, 159
Scahill L. See Morshed SA
Schaefer SM. See Rusch BD
Scharf BA. See Coplan JD
Schelling G, Briegel J, Roozendaal B, Stoll C, Rothenhäusler H-B.

Kapfhammer H-P. The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder in survivors, 978
Schmand B. See Reneman L
Schönfeldt-Lecuona C, See Herwig U
Schubert V. See Graf A
Schuff N, Neylan TC, Lenoci MA, Du AT, Weiss DS, Marmar CR, Weiner MW. Decreased hippocampal *N*-acetylaspartate in the absence of atrophy in posttraumatic stress disorder, 952
Schwarcz R, Rassoulpour A, Wu H-Q, Medoff D, Tamminga CA, Roberts RC. Increased cortical kynurenate content in schizophrenia, 521
Schwartz PJ, Rosenthal NE, Wehr TA. Band-specific electroencephalogram and brain cooling abnormalities during NREM sleep in patients with winter depression, 627
Schweizer E. See Furlan PM
Seeman P. See Kapur S
Seidman LJ. See Kremen WS
Seidman LJ. See Stone WS
Seidman SN, Araujo AB, Roose SP, McKinlay JB. Testosterone level, androgen receptor polymorphism, and depressive symptoms in middle-aged men, 371
Self DW. See Chambers RA
Serio A. See Nacmias B
Serretti A. See Zanardi R
Sharma T. See Narr KL
Sharp R. See Swerdlow NR
Sharp T. See Dawe GS
Shastri A. See Nahas Z
Sheline YI, Barch DM, Donnelly JM, Ollinger JM, Snyder AZ, Mintum MA. Increased anygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study, 651
Shin LM, Whalen PJ, Pitman RK, Bush G, Macklin ML, Lasko NB, Orr SP, McInerney SC, Rauch SL. An fMRI study of anterior cingulate function in posttraumatic stress disorder, 933
Shirakawa O. See Nishiguchi N
Shoaf S. See Dvoskin R
Siegel GI. See Levitan RD
Sieghart W. See Willeit M
Siever LJ. See New AS
Silverman J. See New AS
Simosky JK, Stevens KE, Kem WR, Freedman R. Intragastric DMXB-A, an α7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice, 493
Singh B. See Veakoulis D
Siu K-P. See Yoon I-S
Smeraldi E. See Zanardi R
Smith AM. See Kiehl KA
Smith BJ. See Velakoulis D
Smith ELP. See Coplan JD
Snyder AZ. See Sheline YI
Snyder-Kastenberg J. See Szuba MP
Soares JC. See Sassi RB
Song D. See Grados MA
Sorbi S. See Nacmias B
Southwick SM. See Rasmusson AM
Soyka M. See Preuss UW
Spencer T. See Faraone SV
Spitzer M. See Herwig U
Stahl SM. Forced titration as a confound in an SSRI comparator study of sertraline versus citalopram in the treatment of major depressive disorder, 66–corr (reply)
Stastny J. See Willeit M
Steffens DC. See Ahearn EP
Steffens DC. See Taylor WD
Steffens DC, McQuoid DR, Krishnan KRR. Hippocampal volume and cognitiion in geriatric depression, 68–corr (reply)
Steffens DC, Wagner HR, Levy RM, Horn KA, Krishnan KRR. Performance feedback deficit in geriatric depression, 358
Stevens KE. See Simosky JK
Stoll C. See Schelling G
Stone WS, Faraone SV, Seidman LJ, Green AI, Wojcik JD, Tsuang MT. Concurrent validation of schizotaxia: a pilot study, 434
Stowe ZN. See Hendrick V
Stuart GW. See Velakoulis D
Suomi SJ. See Dvoskin R
Suri R. See Hendrick V
Suzuki K. See Nishiguchi N
Sweeney JA. See Grant MM
Swerdlow NR, Karban B, Ploum Y, Sharp R, Geyer MA, Eastvold A. Tactile prepuff inhibition of startle in children with Tourette's syndrome: in search of an "fMRI-friendly" startle paradigm, 578
Szabo ST, Blier P. Effects of chronic antidepressant drug administration and electroconvulsive shock on locus coeruleus electrophysiologic activity, 644–corr
Szeszko PR. See Pine DS
Szuba MP, O'Reardon JP, Rai AS, Snyder-Kastenberg J, Amsterdam JD, Gettes DR, Wassermann EM, Evans DL. Acute mood and thyroid stimulating hormone effects of transcranial magnetic stimulation in major depression, 22

Tamminga CA. See Schwarcz R
Tan C-H. See Tan E-C
Tan E-C, Chong S-A, Mahendran R, Dong F, Tan C-H. Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor, 144
Tang CY. See Hazlett EA
Tascedda F. Blom JMC, Brunello N, Zolin K, Gennarelli M, Colzi A, Bravi D, Carra S, Racagni G, Riva MA. Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats, 117
Tauscher J. See Willeit M
Taylor JR, Jentsch JD. Repeated intermittent administration of psychomotor stimulant drugs alters the acquisition of Pavlovian approach behavior in rats: differential effects of cocaine, *d*-amphetamine and 3,4-methylenedioxymethamphetamine ("Ecstasy"), 137
Taylor WD, Payne ME, Krishnan KRR, Wagner HR, Provenzale JM, Steffens DC, MacFall JR. Evidence of white matter tract disruption in MRI hyperintensities, 179
Tedde A. See Nacmias B
Tekumalla PK, Calon F, Rahman Z, Birdi S, Rajput AH, Hornykiewicz O, Di Paolo T, Bédard PJ, Nestler EJ. Elevated levels of ΔFosB and RGS9 in striatum in Parkinson's disease, 813
Teneback C. See Nahas Z
Ten Have T. See Morrison MG
Tenke CE. See Bruder GE
Thase ME. See Grant MM
Thase ME. See Lavori PW
Thijssen JPP, Van Goozen SHM, Van Engeland H, Matute LMP,

Blankenstein MA. No detectable prolactin in human saliva, 817–corr
Thome J, Pesold B, Baader M, Hu M, Gewirtz JC, Duman RS, Henn FA. Stress differentially regulates synaptophysin and synaptotagmin expression in hippocampus, 809
Thompson PM. See Narr KL
Thorell L-H. See Aardal-Eriksson E
Thron A. See Herpertz SC
Tiraboschi E. See Consogno E
Todd RD, Botteron KN. Is attention-deficit/hyperactivity disorder an energy deficiency syndrome?, 151
Todtenkopf M. See Benes FM
Toga AW. See Narr KL
Trivedi M. See Lavori PW
Trottini M. See Fabian TJ
Tsuang MT. See Kremen WS
Tsuang MT. See Stone WS

Unger J. See Herwig U

van Buchem MA. See van den Heuvel DMJ
van Calker D. See Gann H
van de Laar N, Henter I, Bartko JJ, Wyatt RJ. Adverse events during a placebo phase for inpatients with chronic schizophrenia, 487
van den Brink W. See Reneman L
van den Heuvel DMJ, van der Flier WM, Bollen ELEM, van Buchem MA, Middelkoop HAM. Hippocampal volume and cognition in geriatric depression, 68–corr
van den Hoofdakker RH. See Koorengevel KM
van der Flier WM. See van den Heuvel DMJ
van der Geest JN, Kemner C, Camfferman G, Verbaten MN, van Engeland H. Eye movements, visual attention, and autism: a saccadic reaction time study using the gap and overlap paradigm, 614
Vandergriff JL. See Dawe GS
Van Engeland H. See Thijssen JPP
van Engeland H. See van der Geest JN
Van Gestel S. See van Os J
Van Goozen SHM. See Thijssen JPP
Van Heertum R. See Parsey RV
van Os J, Wichers M, Danckaerts M, Van Gestel S, Derom C, Vlietinck R. A prospective twin study of birth weight discordance and child problem behavior, 593
Varoquaux O. See Quintin P
Velakoulis D, Stuart GW, Wood SJ, Smith DJ, Brewer WJ, Desmond P, Singh B, Copolov D, Pantelis C. Selective bilateral hippocampal volume loss in chronic schizophrenia, 531
Verbaten MN. See van der Geest JN
Vincent DJ. See Nahas Z
Vincent SL. See Benes FM
Vitiello MV. See Avery DH
Vlietinck R. See van Os J
Vojvoda D. See Rasmusson AM

Wagner HR. See Taylor WD
Walker ML. See Levitan RD
Walkup JT. See Grados MA
Wall TL. See Ehlers CL
Wallner C. See Graf A
Wang H-Y, Friedman E. Increased association of brain protein kinase C with the receptor for activated C kinase-1 (RACK1) in bipolar affective disorder, 364
Wang J-F. See Chen B
Wang S. See Rasmusson AM
Warsh JJ. See Yoon I-S
Wassermann E. See Szuba MP
Wassermann EM, Greenberg BD, Nguyen MB, Murphy DL. Motor cortex excitability correlates with an anxiety-related personality trait, 377
Waterhouse L. See Green L
Weems CF. See Carrion VG
Wehr TA. See Schwartz PJ
Wei T-C. See Hazlett EA
Weinbach J. See Wirshing DA
Weinberger DR. See Egan MF
Weinberger DR. See Winterer G
Weinberger DR, Egan MF, Bertolino A. Callicott JH, Mattay VS, Lipska BK, Berman KF, Goldberg TE. Prefrontal neurons and the genetics of schizophrenia, 825
Weiner MW. See Schuff N
Weinstein LS. The role of tissue-specific imprinting as a source of phenotypic heterogeneity in human disease, 927
Weirich M. See Egan MF
Weisler RH. See Ahearn EP
Weiss DS. See Schuff N
Weiss JM, Grant MM. Effects of chronic antidepressant drug administration and electroconvulsive shock on locus coeruleus electrophysiologic activity, 644–corr (reply)
Wenning B. See Herpertz SC
Westerink BHC. See Cremers TIFH
Whalen PJ. See Shin LM
Whitfield S. See Ford JM
Wichers M. See van Os J
Wienbruch C. See Fehr T
Wiersma LJ. See Cremers TIFH
Wikström HV. See Cremers TIFH
Wilens T. See Faraone SV
Wilkinson CW. See Kanter ED
Willeit M. See Graf A
Willeit M, Stastny J, Pirker W, Praschak-Rieder N, Neumeister A, Asenbaum S, Tauscher J, Fuchs K, Sieghart W, Hornik K, Aschauer HN, Brücke T, Kasper S. No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism, 8
Willmes K. See Herpertz SC
Wilson GV. See Austen ML
Winterer G, Egan MF, Rädler T. Coppola R, Weinberger DR. Event-related potentials and genetic risk for schizophrenia, 407
Wirshing DA, Pierre JM, Eyeler J, Weinbach J, Wirshing WC. Risperidone-associated new-onset diabetes, 148
Wirshing WC. See Wirshing DA
Wisniewski SR. See Lavori PW
Wlk W. See Graf A
Wojcik JD. See Stone WS
Wolkowitz OM. See Neylan TC
Wood SJ. See Velakoulis D
Woodside DB. See Levitan RD
Wu H-M. See Saxena S
Wu H-Q. See Schwarcz R
Wyatt RJ. See van de Laar N

Yazgan Y. See Morshed SA
Yildiz A, Demopulos CM, Moore CM, Renshaw PF, Sachs GS. Effect of lithium on phosphoinositide metabolism in human brain: a proton decoupled ^{31}P magnetic resonance spectroscopy study, 3
Yoon I-S, Li PP, Siu K-P, Kennedy JL, Macciardi F, Cooke RG, Parikh SV, Warsh JJ. Altered TRPC7 gene expression in bipolar-I disorder, 620
Young AH. See Montgomery AJ
Young LT. See Chen B

Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, Dotoli D, Smeraldi E. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression, 323

Zea-Ponce Y. See Parsey RV
Zhang H. See Morshed SA
Zmuda MD. See Fabian TJ
Zolin K. See Tascedda F

Subject Index to Volume 50

N-Acetylaspartate
  hippocampal levels in posttraumatic stress disorder, 952
  prefrontal levels in Ecstasy users, 550
ACTH levels
  in posttraumatic stress disorder, 238
  in premenopausal women, 965
S-Adenosylmethionine
  affecting presynaptic signaling, 337
Adolescents
  chronic depression in 8–16 year olds, 351
  EEG asymmetry in Native Americans, 129
  fears as predictors of depression, 721
  frontal cortex dysfunction in conduct disorder, 600
Adrenal glands
  in posttraumatic stress disorder
    cortical responsiveness in, 238
    reactivity in premenopausal women, 965
β-Adrenoceptors
  pindolol interaction with, 13
Affective stimuli
  and limbic activation in psychopathy, 678
Age
  cognition in depressed young adults, 35
Aggressivity
  and HTR1B genotype, 62
  and monoamine metabolites in cerebrospinal fluid, 783
Aging
  and atypical antipsychotics in behavioral disturbances, 912
  depression in. *See* Depression, geriatric
  and depressive symptoms in middle-aged men, 371
  and DHEA levels in depression
    in elderly persons, 767
    at perimenopause, 705
Alcohol dependence
  and EEG asymmetry in Native American youth, 129
  sleep disorders in, 383
  and suicide attempts associated with 5-HTT promoter polymorphism S-allele, 636
Alpha activity
  EEG asymmetry in Native American youth, 129
Alzheimer's disease
  genetic factors related to psychotic symptoms in, 472, 821 (correction)
[γ-]Aminobutyric acid
  and motor evoked potentials from magnetic pulses, 377
cAMP
  and cytokine production affected by lithium, 217
Amphetamine
  and dopamine transmission in depression, 313
  and Pavlovian learning in rats, 137
Amygdala
  activation in borderline personality disorder, 292
  activity in psychopathy, 678
  drugs affecting, and Pavlovian learning in rats, 137
  increased activation in depression, 651
  mapping in schizophrenia, 84
  volumes in posttraumatic stress disorder from pediatric maltreatment, 305
Androgen
  receptor polymorphism in male depression, 371
Angelman syndrome
  tissue-specific imprinting in, 927
Animal studies
  development of posttraumatic stress disorder, 231
  DMXB-A affecting sensory gating in DBA/2 mice, 493
  dopamine D1 receptor actions in monkeys, 501
  elevated CSF levels of corticotropin-releasing factor in adults after early stress, 200
  glutamate receptor modulation by olanzapine in rats, 117
  locus coeruleus activation by olanzapine in rats, 510
  neurokinin-1 receptor blockade affecting serotonin neurotransmission, 191
  Pavlovian learning affected by psychomotor stimulant drugs, 137
  pindolol interaction with paroxetine, 13
  role and targets of schizophrenia models, 845
  sensorimotor gating in vasopressin-deficient rats, 425
  sensory gating affected by nicotinic agonist in DBA/2 mice, 493
  stress affecting memory and yohimbine sensitivity in rats, 994
Anticipation
  in attention-deficit/hyperactivity disorder, 44
Antidepressants
  S-adenosylmethionine affecting presynaptic signaling, 337
  and amygdala activation in depression, 651
  binding profile of escitamopram and *R*-fluoxetine, 345
  and brain derived neurotrophic factor levels in brain, 260
  exposure of infants to fluoxetine through breast milk, 775
  factors affecting fluvoxamine activity, 323
  and locus coeruleus electrophysiology, 644–corr
  substance P antagonist affecting serotonin neurotransmission, 191
Antipsychotic agents. See also specific drugs
  affecting neuroplasticity, 729
  atypical
    broad therapeutic uses of, 912
    and neurobiology of schizophrenia, 823–ed
  dopamine D_2 receptors affecting, 873

Abbreviations:
ed: editorial
corr: correspondence

© 2001 Society of Biological Psychiatry

0006-3223/01/$20.00
PII S0006-3223(01)01339-7

haloperidol affecting sensorimotor gating in vasopressin-deficient rats, 425
neurotensin affecting action of, 856
olanzapine activation of locus coeruleus in rats, 510
parkinsonism from, substantia nigra echogenicity in, 463
and phencyclidine-activated glutamate efflux in prefrontal cortex, 750
treatment resistance in schizophrenia, 898
Anxiety
and adolescent fears as predictors of depression, 721
and hippocampal volume in depression, 960
motor cortex excitability in, 377
parental, and fear conditioning in children, 225
related to brain metabolic changes in depression, 171
and stress affecting memory and yohimbine sensitivity in rats, 994
substance P antagonist affecting, 191
Astrocytes
catecholamine receptors in attention-deficit/hyperactivity disorder, 151
Asymmetry
in EEG studies of Native American youth, 129
frontal lobe, in children with posttraumatic stress disorder, 943
in mapping of anatomical systems in schizophrenia, 84
Attention
and prepulse inhibition of startle reflex, 281
Attention-deficit/hyperactivity disorder
behavioral performance and event-related potentials in, 44
as energy deficiency syndrome, 151
ocular fixation task in, 633
and psychiatric comorbidity in girls and boys, 586
Auditory event-related potentials
and effects of DMXB-A on DBA/2 mice, 493
and genetic risk for schizophrenia, 407
P50 suppression and schizotypal beliefs, 441
in schizophrenia subtypes, 447
and self-monitoring of speech in schizophrenia, 540
Autism
oxytocin peptide forms in, 609
saccadic gap effect in, 614
Autoantibodies
in tic disorders, 566
Autonomic nervous system
in seasonal affective disorder, 28

B-lymphoblastoid cell lines
TRPC7 gene expression in bipolar-I patients, 620
Beckwith-Wiedemann syndrome
tissue-specific imprinting in, 927
Behavioral disorders
atypical antipsychotics in, 912
Biological Psychiatry
new features in, 1–ed
Bipolar disorder
antidepressants affecting brain derived neurotrophic factor levels, 260
brain protein kinase C activation in, 364
cingulate cortex cell counts in, 395
decreased pituitary volume in, 271
evaluation of three self-rating scales in acute mania, 468
sensorimotor gating in, 418
TRPC7 gene expression in bipolar-I patients, 620
and tryptophan depletion in relatives of patients, 184
Birth weight
low weight as risk for childhood psychopathology, 593
Blood flow, cerebral
in flashbacks in posttraumatic stress disorder, 246
velocity in untreated panic disorder, 299
Blood pressure
in seasonal affective disorder, 28
Body mass
and 5-HTR1B receptor gene associated with bulimia nervosa, 640
Borderline personality disorder
amygdala activation in, 292
and serotonin 2A receptor gene polymorphism in Japan, 123
Brain
N-acetylaspartate levels in Ecstasy users, 550
amygdala activation in borderline personality disorder, 292
antidepressants affecting brain derived neurotrophic factor levels, 260
blood flow velocity in untreated panic disorder, 299
cortical kynurenate levels in schizophrenia, 521
diffusion tensor imaging in hyperintensities, 179
EEG abnormalities during sleep in seasonal affective disorder, 627
energy metabolism in attention-deficit/hyperactivity disorder, 151
increased amygdala activation in depression, 651
inositol monophosphatase metabolism affected by lithium, 3
intensity-dependent bilateral effects of transcranial magnetic stimulation, 712
metabolism in depression and obsessive-compulsive disorder, 159
perinatal neuronal injury from cytokines as schizophrenia risk, 743
PET predictors of response to cingulotomy, 659
prefrontal *N*-acetylaspartate levels in Ecstasy users, 550
protein kinase C activation in bipolar disorder, 364
regional blood flow in flashbacks in posttraumatic stress disorder, 246
thalamic activation in prepulse inhibition, 281
volume of
haloperidol affecting, 729
reduction in neuroticism, 685
Breast-feeding
and exposure of infants to fluoxetine, 775
Bulimia nervosa
and 5-HTR1B receptor gene associated with body mass, 640

Calcium homeostasis
and TRPC7 gene expression in bipolar-I disorder, 620

CANTAB studies
in depressed young adults, 35
Catechol *O*-methyltransferase
genotype affecting prefrontal neurons, 825
Catecholamines
and neuronal energy in attention-deficit/hyperactivity disorder, 151
Caudate nucleus
elevated levels of ΔFosB and RGS9 in Parkinson's disease, 813
Cell firing
olanzapine affecting, in rat locus coeruleus, 510
Cerebral cortex
kynurenate levels in schizophrenia, 521
Cerebrospinal fluid
corticotropin-releasing factor levels in adult primates after early stress, 200
monoamine metabolite levels in psychopathology, 783
Challenge studies
ethical issues in, 479
Children
atypical antipsychotic agents for, 912
behavioral and motor responses in attention-deficit/hyperactivity disorder, 44
chronic depression in 8–16 year olds, 351
EEG asymmetry in Native Americans, 129
fear conditioning related to anxiety in parents, 225
low birth weight as risk for childhood psychopathology, 593
maltreatment of
and CSF levels of corticotropin-releasing factor in adult primates, 200
and frontal asymmetry in posttraumatic stress disorder, 943
and hippocampal volumes in posttraumatic stress disorder, 305
ocular fixation task in attention-deficit/hyperactivity disorder, 633
oxytocin and autistic disorder, 609
psychiatric comorbidity in girls with attention-deficit/hyperactivity disorder, 586
saccadic eye movements in autism, 614
Cingulate cortex
activity in psychopathy, 678
cell counts in schizophrenia and bipolar disorder, 395
function in posttraumatic stress disorder, 932
Cingulotomy
predictors of responses in obsessive-compulsive disorder, 659
Circadian rhythm
and EEG abnormalities during sleep in seasonal affective disorder, 627
and extraocular light therapy in seasonal affective disorder, 691
β-CIT binding
and serotonin transporter promoter gene region polymorphism, 8
Citalopram
binding to monoamine transporters, 345
compared to sertraline in depression, 66–corr
Clinical trials
equipoise-stratified randomization in, 792
Clozapine
activating locus coeruleus cells, 510
affecting neuroplasticity, 729
and glutamate receptor modulation in rats, 117
and phencyclidine-activated glutamate efflux in prefrontal cortex, 750
therapeutic uses of, 912
Cocaine
and Pavlovian learning in rats, 137
Cognition
in depressed young adults, 35
in geriatric depression, 68–corr
and performance feedback, 358
impairment after ECT predicted by cortisol levels, 331
and light therapy affecting Mini-Mental State Examination scores, 725
risk of impairments in siblings of schizophrenic patients, 98
Comorbidity
in girls and boys with attention-deficit/hyperactivity disorder, 586
substance abuse and schizophrenia, 71
Conduct disorder
and frontal cortex dysfunction in adolescents, 600
Corticosteroids
affecting serotonin-1A receptor number, 668
Corticosterone levels
in posttraumatic stress disorder in animals, 231
Corticotropin-releasing factor
elevated CSF levels in adult primates after early stress, 200
premenopausal levels in posttraumatic stress disorder, 965
Cortisol levels
in chronic depression in 8–16 year olds, 351
and cognitive impairment from electroconvulsive therapy, 331
in posttraumatic stress disorder, 238
premenopausal studies, 965
salivary levels, 986
and response to ipsapirone by females with schizophrenia, 758
salivary
after stress in social phobia, 254
in posttraumatic stress disorder, 986
CP-96,345
affecting serotonin neurotransmission, 191
Cytokines
and perinatal neuronal injury as risk for schizophrenia, 743
production affected by lithium, 217

Dehydroepiandrosterone levels
in chronic depression in 8–16 year olds, 351
in depressed older adults, 767
and depressive symptoms at perimenopause, 705
in posttraumatic stress disorder, 238

Delta activity
in magnetoencephalography in schizophrenia, 108
Dementia
and light therapy affecting Mini-Mental State Examination scores, 725
Dentate gyrus
brain derived neurotrophic factor levels affected by antidepressants, 260
Depression
in bipolar disorder. *See* Bipolar disorder
and corticosteroids affecting 5-HT_{1A} receptor number, 668
DHEA levels in
in elderly persons, 767
at perimenopause, 705
and exposure of infants to fluoxetine through breast milk, 775
geriatric
DHEA levels in, 767
hippocampal volume and cognition in, 68–corr
and MRI correlates of suicide attempts, 266
performance feedback in, 358
in males
symptoms in middle-aged men, 371
testosterone levels and androgen receptor polymorphism in, 371
and substance P antagonist affecting serotonin neurotransmission, 191
in winter. *See* Seasonal affective disorder
Depressive disorder, major
adolescent fears as predictors of, 721
brain metabolism changes with symptom improvement, 171
chronic depression in 8–16 year olds, 351
and cognition in young adults, 35
comparison of citalopram and sertraline in, 66–corr
and cortisol levels predicting cognitive impairment after ECT, 331
and DHEA concentrations in older adults, 767
and diffusion characteristics of white matter hyperintensities in MRI, 179
dopamine D_2 receptor availability in, 313
factors affecting fluvoxamine activity in, 323
hippocampal volume in, 960
increased amygdala activation in, 651
and monoamine metabolites in cerebrospinal fluid, 783
relation to obsessive-compulsive disorder, 159
transcranial magnetic stimulation in, 22
TRPC7 gene expression in bipolar-I patients, 620
Developmental stages
chronic depression in 8–16 year olds, 351
and fear conditioning in children of parents with anxiety disorders, 225
and frontal asymmetry in pediatric posttraumatic stress disorder, 943
hippocampal volumes in posttraumatic stress disorder after pediatric maltreatment, 305
DHEA. *See* Dehydroepiandrosterone levels
Diabetes mellitus
risperidone-associated, 148
Dipole modeling
in magnetoencephalography in schizophrenia, 108
Disomy, uniparental
tissue-specific imprinting in, 927
DMXB-A
and sensory gating in DBA/2 mice, 493
DNA methylation
in regions of imprinted genes, 927
Dopamine
D1 receptor actions in monkeys, 501
D2 receptors
affecting atypical antipsychotics, 873
availability in depression, 313
ketamine affinity for, 555–corr
system denervation affecting ΔFosB and RGS9 levels in striatum, 813
Dorsal raphe
serotonin neurons affected by substance P antagonist, 191
Drug addiction. *See* Substance abuse
DSM-IV
stressor criterion in posttraumatic stress disorder, 699
Dyskinesia
and elevated levels of ΔFosB and RGS9 in Parkinson's disease, 813
tardive, and polymorphism of 5-HT receptor, 144

Eating disorders
5-HTR1B receptor gene associated with body mass in bulimia nervosa, 640
and serotonin 2A receptor gene polymorphism in Japan, 123
Ecstasy (MDMA)
and memory deficits related to prefrontal *N*-acetylaspartate levels, 550
and Pavlovian learning in rats, 137
Education
teaching research bioethics, 802
Elderly persons. *See* Aging
Electroconvulsive therapy
and cortisol levels predicting cognitive impairment, 331
and locus coeruleus electrophysiology, 644–corr
Electroencephalogram
abnormalities during sleep in seasonal affective disorder, 627
asymmetry in Native American youth, 129
Emotions
and amygdala activation
in borderline personality disorder, 292
in depression, 651
and anterior cingulate function in posttraumatic stress disorder, 932
and limbic abnormalities in pscyhopathy, 678
Energy
brain metabolism in attention-deficit/hyperactivity disorder, 151
Equipoise strata
analysis in clinical trials, 792

Errata
Nacmias article (2001;50:472–475), 821
Parveen article (2001;50:566–577), 1010
Rosenberg article (2000;48:294–300), 312
Shapleske article (2001;49:685–693), 394
Silberg article (2001;49:1040–1049), 393
Escitalopram
binding to monoamine transporters, 345
Ethics
and symptom provocation procedures in research, 479
teaching research bioethics, 802
Event-related potentials
auditory
and effects of DMXB-A on DBA/2 mice, 493
and genetic risk for schizophrenia, 407
P3 amplitude in schizophrenia subtypes, 447
P50 suppression and schizotypal beliefs, 441
and self-monitoring of speech in schizophrenia, 540
visual
in attention-deficit/hyperactivity disorder, 44
P300 sources in adolescents with conduct disorder, 600
Evoked potentials
motor, in anxiety disorders, 377
Executive functioning
in depressed young adults, 35
Extrapyramidal side effects
from dopamine D1 antagonists and agonists, 501
Eye movements
ocular fixation task in attention-deficit/hyperactivity disorder, 633
saccadic gap effect in autism, 614

Families
cognitive impairment in siblings of schizophrenic patients, 98
early neglect affecting CSF levels of corticotropin-releasing factor in adult primates, 200
fear conditioning in children of parents with anxiety disorders, 225
obsessive-compulsive disorder and tic disorders in, 559
psychiatric comorbidity in girls with attention-deficit/hyperactivity disorder, 586
tryptophan depletion in relatives of patients with bipolar disorder, 184
validation of schizotaxia, 434
Fear conditioning
developmental studies of, 225
Fears in adolescence
as predictors of depression, 721
Females
5-HT_{1A} receptor dysfunction in schizophrenia, 758
DHEA-S levels in depression at perimenopause, 705
motor cortex excitability in anxiety, 377
premenopausal pituitary and adrenal reactivity in posttraumatic stress disorder, 965
psychiatric comorbidity in girls with attention-deficit/hyperactivity disorder, 586
Fluoxetine
binding to monoamine transporters, 345
concentrations in nursing infants and breast milk, 775
Fluvoxamine
factors affecting antidepressant activity, 323
c-fos proteins
elevated levels of ΔFosB and RGS9 in Parkinson's disease, 813
immunoreactivity affected by olanzapine, 510
Frontal cortex
dysfunction in adolescents with conduct disorder, 600
orbital, in performance feedback in geriatric depression, 358
Frontal lobe
asymmetry in children with posttraumatic stress disorder, 943

Genetics
CAG repeat length in male aging, 371
and development of posttraumatic stress disorder in animals, 231
familial phenotype of obsessive-compulsive disorder, 559
family study of girls with attention-deficit/hyperactivity disorder, 586
gene expression induced by haloperidol, 729
5-HTR1B receptor gene associated with body mass in bulimia nervosa, 640
risk factors for psychotic symptoms in Alzheimer's disease, 472, 821 (correction)
and schizophrenia risk
related to event-related potentials, 407
related to prefrontal neuronal pathology, 825
serotonin transporter promoter gene polymorphism, 8
serotonin type 2A receptor polymorphism
and eating disorders in Japan, 123
and susceptibility to tardive dyskinesia, 144
and suicide attempts
associated with 5-HTT promoter polymorphism S-allele, 636
related to HTR1B genotype, 62
tissue-specific imprinting in human disease, 927
TRPC7 gene expression in bipolar-I disorder, 620
Geriatric conditions. *See* Aging
Glutamate
efflux in prefrontal cortex affected by antipsychotic drugs, 750
receptor function in schizophrenia, 521
receptor modulation by olanzapine in rats, 117
Glycogen
metabolism in attention-deficit/hyperactivity disorder, 151

Habituation
in bipolar disorder, 418
Hallucinations
and self-monitoring of speech in schizophrenia, 540
Haloperidol
affecting neuroplasticity, 729
and glutamate receptor modulation in rats, 117

and phencyclidine-activated glutamate efflux in prefrontal cortex, 750
and sensorimotor gating in vasopressin-deficient rats, 425
Heart rate
in seasonal affective disorder, 28
Hippocampus
abnormalities in substance abuse and schizophrenia, 71
N-acetylaspartate levels in posttraumatic stress disorder, 952
mapping in schizophrenia, 84
metabolism in depression and obsessive-compulsive disorder, 159
serotonin neurotransmission affected by substance P antagonist, 191
shape analysis in schizophrenia, 531
stress affecting synaptic vesicle proteins in, 809
volume studies
in children with posttraumatic stress disorder, 305, 943
and cognition in geriatric depression, 68–corr
in depression, 960
Homovanillic acid
cerebrospinal fluid levels in pscyhopathology, 783
Huntington's disease
atypical antipsychotic agents in, 912
Hydrocortisone
and posttraumatic stress disorder after septic shock, 978
5-Hydroxyindoleacetic acid
cerebrospinal fluid levels in psychopathology, 783
Hyperintensities
diffusion tensor imaging in, 179
Hypothalamic-pituitary-adrenal axis
and adrenocortical response in posttraumatic stress disorder, 238
decreased pituitary volume in bipolar disorder, 271
reactivity in premenopausal posttraumatic stress disorder, 965
and stress affecting salivary cortisol in social phobia, 254
Hypothalamic-pituitary-gonadal axis
and depressive symptoms in middle-aged men, 371
Hypothalamus
oxytocin peptide forms in autistic disorder, 609

Immune system
autoantibodies in tic disorders, 566
and cytokine production affected by lithium, 217
Immunohistochemistry
brain derived neurotrophic factor levels affected by antidepressants, 260
c-fos immunoreactivity affected by olanzapine, 510
Imprinting, genomic
role in human disease, 927
Impulsive aggression
and HTR1B genotype, 62
and monoamine metabolites in cerebrospinal fluid, 783
Indians, North American
EEG asymmetry in adolescents and children, 129
Infants
exposure to fluoxetine through breast milk, 775
Inositol monophosphatase
metabolism in brain affected by lithium, 3
Intelligence quotient
and neuropsychology in schizophrenia, 453
Interleukins
production affected by lithium, 217
Ipsapirone
and 5-HT_{1A} receptor dysfunction in schizophrenia, 758
Isoprenaline
interaction with pindolol, 13

Japan
serotonin 2A receptor gene polymorphism in eating disorders, 123

Ketamine
affinity for NMDA and dopamine D_2 receptors, 555–corr
and glutamate efflux in prefrontal cortex affected by antipsychotic drugs, 750
Kynurenate
cortical levels in schizophrenia, 521

Lactate
and brain energy metabolism in attention-deficit/hyperactivity disorder, 151
Learning
psychomotor stimulants affecting, in rats, 137
Light therapy
dawn simulation and bright light affecting seasonal affective disorder, 204
extraocular light effects in seasonal affective disorder, 691
and Mini-Mental State Examination scores in dementia, 725
Limbic system
abnormalities in psychopathy, 677
Lithium
affecting cytokine production, 217
and phosphoinositide metabolism in brain, 3
Locus coeruleus
activation by olanzapine in rats, 510
electrophysiology affected by antidepressants, 644–corr

Magnetic resonance imaging
brain volume reduction in neuroticism, 685
correlates related to suicide attempts in depression, 266
decreased pituitary volume in bipolar disorder, 271
diffusion characteristics in white matter hyperintensities, 179
frontal asymmetry in children with posttraumatic stress disorder, 943
functional
amygdala activation in borderline personality disorder, 292
anterior cingulate function in posttraumatic stress disorder, 932
in depression with obsessive-compulsive disorder, 159
fear conditioning circuitry in, 225
increased amygdala activation in depression, 651

intensity-dependent bilateral effects of transcranial magnetic stimulation, 712
limbic abnormalities in psychopathy, 677
in prepulse inhibition of startle reflex, 281
in Tourette's syndrome, 578
mapping of systems in schizophrenia, 84
Magnetic resonance spectroscopy
N-acetylaspartate levels
in Ecstasy users, 550
in posttraumatic stress disorder, 952
inositol monophosphatase metabolism affected by lithium, 3
Magnetic stimulation, transcranial
intensity-dependent bilateral effects, 712
in major depression, 22
and motor evoked potentials in anxiety, 377
standard coil positioning in, 58
Magnetoencephalography
in schizophrenia, 108
Males
CAG repeat length in aging, 371
motor cortex excitability in anxiety, 377
psychiatric comorbidity in boys with attention-deficit/hyperactivity disorder, 586
Mania, acute. *See also* Bipolar disorder
evaluation of three self-rating scales in, 468
and sensorimotor gating in bipolar disorder, 418
MDMA (Ecstasy)
and memory deficits related to prefrontal *N*-acetylaspartate levels, 550
and Pavlovian learning in rats, 137
Melatonin
and extraocular light therapy in seasonal affective disorder, 691
Memory
and cognitive impairment in siblings of schizophrenic patients, 98
and cortisol levels predicting cognitive impairment after ECT, 331
in depressed young adults, 35
and prefrontal *N*-acetylaspartate in Ecstasy users, 550
stress affecting, in rats, 994
Menopause
DHEA-S levels in depression at perimenopause, 705
premenopausal pituitary and adrenal reactivity in posttraumatic stress disorder, 965
Metabolism, cerebral
in attention-deficit/hyperactivity disorder, 151
changes with symptom improvement in depression, 171
in depression and obsessive-compulsive disorder, 159
inositol monophosphatase affected by lithium, 3
Methoxy-hydroxy-phenylglycol (MHPG)
cerebrospinal fluid levels in psychopathology, 783
N-Methyl-D-aspartate (NMDA)
ketamine affinity for receptors, 555–corr
receptor function in schizophrenia, 521
Methylenedioxymethamphetamine. *See* Ecstasy
Metyrapone
and adrenocortical response in posttraumatic stress disorder, 238
Molecular mimicry
and autoantibodies in tic disorders, 566
Mood disorders
atypical antipsychotics in, 912
Morphometry
mapping of systems in schizophrenia, 84
Motor cortex
excitability in anxiety, 377
Motor response
in attention-deficit/hyperactivity disorder, 44
Myo-inositol
and cytokine production affected by lithium, 217

Negative symptoms
and validation of schizotaxia, 434
Neurobiology of schizophrenia
and role of atypical antipsychotics, 823–ed
and substance abuse, 71
and synaptic changes from atypical antipsychotics, 729
Neuroimaging
anterior cingulate function in posttraumatic stress disorder, 932
Neurokinin-1
receptor blockade affecting serotonin neurotransmission, 191
Neuroleptics. *See* Antipsychotic agents
Neuronavigation
and coil positioning in transcranial magnetic stimulation, 58
Neurons
nonpyramidal, in cingulate cortex in schizophrenic and bipolar cases, 395
perinatal injury from cytokines as risk for schizophrenia, 743
prefrontal pathology and genetics of schizophrenia, 825
Neuroplasticity
antipsychotic drugs affecting, 729
stress affecting, 809
Neuropsychiatric disorders
atypical antipsychotic agents in, 912
Neuropsychological function
and intelligence quotient in schizophrenia, 453
and validation of schizotaxia, 434
Neurosurgery
predictors of response to cingulotomy in obsessive-compulsive disorder, 659
Neurotensin
affecting action of antipsychotic drugs, 856
role in schizophrenia pathophysiology, 856
Neuroticism
and brain volume reduction, 685
Nicotinic receptors
and effects of DMXB-A on DBA/2 mice, 493
Nigrostriatal system
in neuroleptic-induced parkinsonism, 463

Nucleus accumbens
drugs affecting, and Pavlovian learning in rats, 137
signals in substance abuse and schizophrenia, 71

Obsessive-compulsive disorder
and chronic depression in 8–16 year olds, 351
familial phenotype in relation to tic disorders, 559
motor evoked potentials in, 377
predictors of response to cingulotomy in, 659
relation to major depression, 159
Olanzapine
activating locus coeruleus in rats, 510
affecting neuroplasticity, 729
and glutamate receptor modulation in rats, 117
therapeutic uses of, 912
Orbitofrontal cortex
in performance feedback in geriatric depression, 358
Outcome assessment
adverse events in placebo phase in schizophrenia, 487
Oxytocin
and autistic disorder, 609

P3 amplitude
in adolescents with conduct disorder, 600
and genetic risk for schizophrenia, 407
and motor response in hyperactive children, 44
in schizophrenia subtypes, 447
P50 suppression
and schizotypal beliefs, 441
Panic disorder
untreated, cerebral blood flow velocity in, 299
Paranoid schizophrenia
event-related potentials in, 447
Parents. *See* Families
Parkinson disease
atypical antipsychotic agents in, 912
and elevated levels of ΔFosB and RGS9 in striatum, 813
Parkinsonism
neuroleptic-induced, substantia nigra echogenicity in, 463
Paroxetine
interaction with pindolol, 13
Personality disorders
atypical antipsychotics in, 912
borderline
amygdala activation in, 292
and serotonin 2A receptor polymorphism in Japan, 123
and suicide and aggression related to HTR1B genotype, 62
PET studies
brain metabolism changes with symptom improvement in depression, 171
cerebral blood flow in flashbacks in posttraumatic stress disorder, 246
corticosteroids affecting serotonin-1A receptor number, 668
in depression and obsessive-compulsive disorder, 159
predictors of response to cingulotomy in obsessive-compulsive disorder, 659
Pharmacogenetics
and factors affecting fluvoxamine activity in depression, 323
Phencyclidine
and glutamate efflux in prefrontal cortex affected by antipsychotic drugs, 750
Phobia, social
and stress affecting salivary cortisol, 254
Pindolol
and fluvoxamine activity, 323
interaction with paroxetine, 13
Pituitary gland
decreased volume in bipolar disorder, 271
premenopausal reactivity in posttraumatic stress disorder, 965
Placebo phase in schizophrenia
adverse events in, 487
Posner paradigm
studies in attention-deficit/hyperactivity disorder, 44
Postmortem brain
brain derived neurotrophic factor levels affected by antidepressants, 260
Posttraumatic stress disorder
adrenocortical responsiveness in, 238
anterior cingulate function in, 932
in children
frontal lobe asymmetry in, 943
hippocampal volumes in, 305
development in animal model, 231
hippocampal *N*-acetylaspartate levels in, 952
incidence after hydrocortisone during septic shock 978
premenopausal pituitary and adrenal reactivity in, 965
and regional cerebral blood flow in flashbacks, 246
and stressor criterion in DSM-IV, 699
Prader-Willi syndrome
tissue-specific imprinting in, 927
Prefrontal cortex
N-acetylaspartate levels in Ecstasy users, 550
coil positioning in transcranial magnetic stimulation, 58
energy deficiency in attention-deficit/hyperactivity disorder, 151
intensity-dependent bilateral effects of transcranial magnetic stimulation, 712
metabolism changes with symptom improvement in depression, 171
neuron pathology in, and genetics of schizophrenia, 825
phencyclidine-activated glutamate efflux affected by antipsychotic drugs, 750
Prepulse inhibition
in bipolar disorder, 418
thalamic activation in, 281
in Tourette's syndrome, 578
in vasopressin-deficient rats, 425
Prolactin
assays in saliva, 817–corr
Protein kinase
activity of PKC in bipolar disorder, 364
S-adenosylmethionine affecting CaM kinase II, 337
Protein phosphorylation
S-adenosylmethionine affecting, 337

Pseudohypoparathyroidism
tissue-specific imprinting in, 927
Psychiatric research
and training in bioethics, 802
Psychomotor retardation
related to brain metabolic changes in depression, 171
Psychomotor stimulants
and Pavlovian learning in rats, 137
Psychopaths
limbic abnormalities in, 677
Psychotic symptoms
in Alzheimer's disease, genetic factors in, 472, 821 (correction)
and sensorimotor gating in bipolar disorder, 418
Putamen
elevated levels of ΔFosB and RGS9 in Parkinson's disease, 813

Quetiapine
therapeutic uses of, 912

Race
and DHEA-S levels in depression at perimenopause, 705
Relatives. *See* Families
Research
symptom provocation procedures in, 479
teaching research bioethics, 802
Respiratory sinus arrhythmia
in seasonal affective disorder, 28
RGS proteins
elevated levels of ΔFosB and RGS9 in Parkinson's disease, 813
Risk factors
for cognitive impairments in siblings of schizophrenic patients, 98
low birth weight and childhood psychopathology, 593
for psychotic symptoms in Alzheimer's disease, 472, 821 (correction)
for schizophrenia
perinatal neuronal injury from cytokines, 743
related to event-related potentials, 407
related to prefrontal neuronal pathology, 825
Risperidone
and diabetes development, 148
therapeutic uses of, 912

Saccadic eye movements
in autism, 614
and ocular fixation task in attention-deficit/hyperactivity disorder, 633
Saliva
cortisol levels
after stress in social phobia, 254
in posttraumatic stress disorder, 986
prolactin assays in, 817–corr
Schizophrenia
adverse events during placebo phase, 487
animal models of, 845
antipsychotic drugs in. *See* Antipsychotic agents
cingulate cortex cell counts in, 395
cortical kynurenate levels in, 521
early stages of, 884
genetics of
and prefrontal cortical biology, 825
related to event-related potentials, 407
and glutamate receptor modulation by olanzapine in rats, 117
hippocampal shape analysis in, 531
and 5-HT_{1A} receptor dysfunction in females, 758
intelligence quotient and neuropsychology in, 453
magnetoencephalography in, 108
mapping of anatomical systems in, 84
neurobiology of, and role of atypical antipsychotics, 823–ed
and neuroplasticity induced by antipsychotic drugs, 729
neurotensin role in pathophysiology, 856
and risk of cognitive impairment in siblings, 98
and risperidone-associated diabetes, 148
role of perinatal neuronal injury from cytokines, 743
self-monitoring of speech in, 540
sensory gating affected by DMXB-A in animal model, 493
substance abuse in, 71
treatment resistance in, 898
and validation of schizotaxia, 434
Schizotaxia
validation of, 434
Schizotypal beliefs
and P50 suppression, 441
Seasonal affective disorder
dawn simulation and bright light affecting, 204
and EEG abnormalities in sleep, 627
extraocular light therapy in, 691
and vagal tone in winter, 28
Self-monitoring
speech in schizophrenia, 540
Self-rating scales
comparison of three scales in acute mania, 468
distress after traumatic events, 986
Sensitization
and drugs affecting Pavlovian learning in rats, 137
Sensorimotor gating
in bipolar disorder, 418
in Tourette's syndrome, 578
in vasopressin-deficient rats, 425
Sensory gating
nicotinic agonist affecting, in DBA/2 mice, 493
poor P50 suppression related to schizotypal beliefs, 441
Septic shock
hydrocortisone in, and posttraumatic stress disorder incidence, 978
Serotonin
cerebrospinal fluid levels of 5-HIAA in psychopathology, 783
corticosteroids affecting 5-HT_{1A} receptor number, 668
5-HT_{1A} receptor dysfunction in schizophrenia in females, 758

5-HTR1B receptor gene associated with body mass in bulimia nervosa, 640
M100907 antagonist affecting phencyclidine-activated glutamate efflux in prefrontal cortex, 750
neurotoxic damage with memory deficits in Ecstasy users, 550
neurotransmission
neurokinin-1 receptor blockade affecting, 191
tryptophan depletion affecting, in relatives of patients with bipolar disorder, 184
polymorphism in type 2A receptor
and eating disorders in Japan, 123
and psychotic symptoms in Alzheimer's disease, 472, 821 (correction)
and susceptibility to tardive dyskinesia, 144
reuptake inhibitors
agents compared in depression, 66–corr
binding profile of escitalopram and *R*-fluoxetine, 345
factors affecting fluvoxamine activity, 323
interaction with pindolol, 13
suicide and aggression related to HTR1B genotype, 62
suicide attempts associated with 5-HTT promoter polymorphism S-allele, 636
transporter promoter gene polymorphism
and fluvoxamine antidepressant activity, 323
and SPECT studies in healthy subjects, 8
Sertraline
compared to citalopram in depression, 66–corr
Sex differences
and motor cortex excitability in anxiety, 377
Shock, septic
hydrocortisone in, and posttraumatic stress disorder incidence, 978
Siblings. *See* Families
SKF 83822 and 83959
behavioral effects in monkeys, 501
Skin conductance level
in seasonal affective disorder, 28
Sleep
and EEG abnormalities in seasonal affective disorder, 627
REM abnormalities in alcohol dependence, 383
Slow waves, neuromagnetic
in schizophrenia, 108
Social phobia
and stress affecting salivary cortisol, 254
SPECT studies
dopamine transmission in depression, 313
serotonin transporter promoter gene genotype distribution, 8
Startle reflex
in bipolar disorder, 418
and prepulse inhibition in Tourette's syndrome, 578
and thalamic activation in prepulse inhibition, 281
in vasopressin-deficient rats, 425
Statistics
and equipoise strata analysis in clinical trials, 792
Streptococcal infections
and autoantibodies in tic disorders, 566
Stress
and brain volume reduction, 685
early neglect affecting CSF levels of corticotropin-releasing factor in adult primates, 200
effects on memory and yohimbine sensitivity in rats, 994
posttraumatic. *See* Posttraumatic stress disorder
and salivary cortisol levels in social phobia, 254
stressor criterion in posttraumatic stress disorder, 699
and synaptic vesicle proteins in hippocampus, 809
Striatum
elevated levels of ΔFosB and RGS9 in Parkinson's disease, 813
Substance abuse
alcohol dependence in. *See* Alcohol dependence
drug addiction affecting Pavlovian learning in rats, 137
memory deficits related to prefrontal *N*-acetylaspartate levels after Ecstasy use, 550
in schizophrenia, 71
Substance P
antagonist affecting serotonin neurotransmission, 191
Substantia nigra
echogenicity in neuroleptic-induced parkinsonism, 463
Suicide attempts
association with 5-HTT promoter polymorphism S-allele, 636
and HTR1B genotype, 62
and monoamine metabolites in cerebrospinal fluid, 783
related to MRI findings, 266
Sydenham's chorea
autoantibodies in, 566
Symptom provocation
procedures in medical research, 479
Synapsin I
S-adenosylmethionine affecting, 337
Synaptic plasticity
antipsychotic drugs affecting, 729
stress affecting, 809

Tardive dyskinesia
and polymorphism of 5-HT receptor, 144
Temperature of body
brain cooling during sleep in seasonal affective disorder, 627
light therapy affecting, in demented patients, 725
and response to ipsapirone by females with schizophrenia, 758
Testosterone levels
in male depression, 371
Thalamus
metabolism in depression and obsessive-compulsive disorder, 159
in prepulse inhibition of startle reflex, 281
Thermoregulation
and EEG abnormalities during sleep in seasonal affective disorder, 627
Theta activity
in magnetoencephalography in schizophrenia, 108

Thyroid stimulating hormone
transcranial magnetic stimulation affecting, in depression, 22
Tic disorders
autoantibodies in, 566
and obsessive-compulsive disorder, 559
prepulse inhibition in Tourette's syndrome, 578
Tourette's syndrome
autoantibodies in, 566
and obsessive-compulsive disorder, 559
prepulse inhibition of startle in, 578
Trail making test
and performance feedback in geriatric depression, 358
Tryptophan
depletion in relatives of patients with bipolar disorder, 184
Twin studies
low birth weight as risk for childhood psychopathology, 593

Ultrasonography
substantia nigra echogenicity in neuroleptic-induced parkinsonism, 463
transcranial Doppler studies in untreated panic disorder, 299

Vagal tone
in seasonal affective disorder, 28
Vasopressin
deficiency in rats affecting sensorimotor gating, 425
Ventricles of brain
mapping in schizophrenia, 84
Visual attention
and saccadic eye movements in autism, 614
Visual event-related potentials
in attention-deficit/hyperactivity disorder, 44
P300 sources in adolescents with conduct disorder, 600
Winter depression. *See* Seasonal affective disorder

Yohimbine sensitivity
stress affecting, in rats, 994

Ziprasidone
therapeutic uses of, 912